Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of WVE-120101 in early manifest Huntington's disease
2019-003637-42Phase 2Terminated
- Sponsor
- Wave Life Sciences
- Start
- Feb 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rovanersen in Huntington disease (HD), sponsored by Wave Life Sciences. Primary endpoint: Safety and tolerability. Started Feb 2020; status: terminated.
02
Drugs
rovanersen
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2019-003637-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003637-42.